<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00853151</url>
  </required_header>
  <id_info>
    <org_study_id>12758</org_study_id>
    <secondary_id>I3H-MC-GAFA(b)</secondary_id>
    <nct_id>NCT00853151</nct_id>
  </id_info>
  <brief_title>A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes</brief_title>
  <official_title>A Proof of Concept Study to Evaluate the Coadministration of TT223 Given Daily and LY2428757 Given Once-Weekly for Four Weeks in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Transition Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Test the safety, tolerability and improvement of blood sugar control with combination therapy
      in individuals with Type 2 Diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 6-Month Endpoint</measure>
    <time_frame>Baseline (Week -1), 6 months</time_frame>
    <description>Values obtained from repeated measures analysis, which included the fixed categorical effects of treatment, baseline therapy strata (metformin versus diet and exercise [D&amp;E]), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline glycosylated hemoglobin (HbA1c). Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 4-Week Endpoint</measure>
    <time_frame>Baseline (Week -1), 4 weeks</time_frame>
    <description>Values obtained from repeated measures analysis, which included the fixed categorical effects of treatment, baseline therapy strata (metformin versus diet and exercise [D&amp;E]), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline glycosylated hemoglobin (HbA1c). Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mixed-Meal Tolerance Test (MMTT) Response - Glucose Area Under the Curve (AUC) at 3-Week and 6-Month Endpoints</measure>
    <time_frame>Baseline (Week -1), 3 weeks, 6 months</time_frame>
    <description>Standardized mixed-meal tolerance test (MMTT) used to assess changes in function of cells that make insulin (pancreatic beta cell function). Area under the plasma glucose concentration versus time curve calculated using linear-trapezoidal method. AUC for glucose represents area under curve of values when plotted over time. Larger area under the curve values represent greater average glucose value over time in response to meal. Least squares (LS) means adjusted for baseline, treatment, visit, treatment-by-visit. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mixed-Meal Tolerance Test (MMTT) Response - C-Peptide Area Under the Curve (AUC) at 3-Week and 6-Month Endpoints</measure>
    <time_frame>Baseline (Week -1), 3 weeks, 6 months</time_frame>
    <description>The area under the C-peptide concentration versus time curve was calculated using the linear-trapezoidal method. Area under the curve (AUC) for C-peptide represents area under the curve (AUC) of C-peptide values when plotted over time. Larger area under the curve (AUC) values represent a greater average C-peptide value over time in response to a meal. Least squares (LS) means adjusted for baseline, treatment, visit, treatment-by-visit interaction. Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mixed Meal Tolerance Test (MMTT) Response - Ratio of Insulin Area Under the Curve (AUC)/Glucose Area Under the Curve (AUC) at 3-Week and 6-Month Endpoints</measure>
    <time_frame>Baseline (Week -1), 3 weeks, 6 months</time_frame>
    <description>Mixed meal tolerance test (MMTT) to assess changes in function of cells making insulin. AUCinsulin/AUCglucose ratio: index of insulin secretion. Larger values reflect greater secretion adjusted for glucose in response to meal. Area under insulin concentration versus time curve and area under plasma glucose concentration versus time curve calculated using linear-trapezoidal method. AUC for insulin and glucose represents AUC of values plotted over time. LS means adjusted for baseline, treatment, visit, treatment-by-visit. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mixed-Meal Tolerance Test (MMTT) Response - Glucagon Area Under the Curve (AUC) at 3-Week and 6-Month Endpoints</measure>
    <time_frame>Baseline (Week -1), 3 weeks, 6 months</time_frame>
    <description>Standardized mixed meal tolerance test (MMTT) to assess changes in hormones in response to meal. Area under the plasma glucagon concentration versus time curve was calculated using the linear-trapezoidal method. Area under the curve (AUC) for glucagon represents the AUC of glucagon values when are plotted over time. Larger area under the curve (AUC) values represent a greater average glucagon value over time in response to a meal. Least squares (LS) means adjusted for baseline, treatment, visit, treatment-by-visit. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mixed-Meal Tolerance Test (MMTT) Response - Glucagon-like Peptide-1 (GLP-1) Area Under the Cure (AUC) at 3-Week and 6-Month Endpoints</measure>
    <time_frame>Baseline (Week -1), 3 weeks, 6 months</time_frame>
    <description>Standardized mixed meal tolerance test (MMTT) to assess changes in hormones in response to meal. Area under plasma glucagon-like peptide-1 (GLP-1) concentration versus time curve calculated using linear-trapezoidal method. Area under the curve (AUC) for glucagon-like peptide-1 (GLP-1) represents the AUC of GLP-1 values when plotted over time. Larger AUC values represent a greater average GLP-1 value over time in response to meal. Least squares (LS) means adjusted for baseline, treatment, visit, treatment-by-visit. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mixed-Meal Tolerance Test (MMTT) Response - Post-Prandial Glucose at 3-Week and 6-Month Endpoints</measure>
    <time_frame>Baseline (Week -1), 3 weeks, 6 months</time_frame>
    <description>Standardized MMTT to assess changes in function of cells that make insulin (pancreatic beta cells). Glucose measured at 2-hour timepoint during MMTT reflects glucose values in response to meal. Change in postprandial glucose calculated based on difference of 2-hour postprandial glucose at endpoint compared to baseline. Larger changes from baseline represent a greater postprandial glucose compared to 2-hour timepoint prior to treatment. Least squares (LS) means adjusted for baseline, treatment, visit, treatment-by-visit. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Blood Glucose (FBG) at 4-Week and 6-Month Endpoints</measure>
    <time_frame>Baseline (Week -1), 4 weeks, 6 months</time_frame>
    <description>Values obtained from repeated measures analysis, which included the fixed categorical effects of treatment, baseline therapy strata (metformin versus diet and exercise [D&amp;E]), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline fasting blood glucose (FBG). Fasting blood glucose (FBG) is the mixed meal tolerance test (MMTT) glucose assessment at time point 0, where available, otherwise it is the assessment taken from the chemistry panel. Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (HbA1C) Adjusted for Baseline Glycosylated Hemoglobin (HbA1c), C-Peptide Level, Homeostasis Model Assessment of Insulin Resistance (HOMA), Duration of Diabetes, and Body Mass Index (BMI) at 6-Month Endpoint</measure>
    <time_frame>Baseline (Week -1), 6 months</time_frame>
    <description>HbA1c adjusted: baseline HbA1c (&lt;8%,≥8%); C-peptide level (normal, elevated); HOMA (&lt;baseline median,≥baseline median); duration diabetes (&lt;3,3-10,&gt;10 years); BMI (&lt;30,≥30). BMI estimates body fat based on weight/height squared. HOMA: index of function of cells that make insulin/insulin resistance. Indices derived from fasting glucose and insulin concentrations. LS means adjusted for treatment, baseline therapy, visit, treatment-by-visit, subgroup, subgroup-by-treatment, subgroup-by-visit, subgroup-by-treatment-by-visit. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in MMTT Response (Postprandial Glucose, Glucose AUC, Insulin/c-Peptide Secretory Response, HOMA, GLP-1, Glucagon) Adjusted for Baseline HbA1c, C-Peptide Level, HOMA, Duration of Diabetes, Weight at Week 0, 3, Month 3.5, 6 Endpoints</measure>
    <time_frame>Baseline (Week -1), Week 0, 3 weeks, 3.5 months, 6 months</time_frame>
    <description>Subgroup analyses for mixed meal tolerance test (MMTT) response (adjusted for baseline glycosylated hemoglobin (HbA1c), C-peptide level, Homeostasis Model Assessment of Insulin Resistance (HOMA), duration of diabetes, weight) not performed due to lack of statistically significant findings in subgroup analysis for HbA1c analyses. HOMA was not done for mixed meal tolerance test (MMTT) because it is not calculated from the mixed meal tolerance test (MMTT). It is reported separately as a secondary outcome measure. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Blood Glucose (FBG) Adjusted for Baseline HbA1c, C-Peptide Level, Homeostasis Model Assessment of Insulin Resistance, Duration of Diabetes, and Weight at 3-Week, 4-Week, 2-Month, 3.5-Month, 5-Month, and 6-Month Endpoints</measure>
    <time_frame>Baseline (Week -1), 3 weeks, 4 weeks, 2 months, 3.5 months, 5 months, 6 months</time_frame>
    <description>The subgroup analyses for fasting blood glucose (FBG) (adjusted for baseline glycosylated hemoglobin [HbA1c]), C-peptide level, homeostasis model assessment of insulin resistance (HOMA), duration of diabetes, and weight) were not performed due to the lack of statistically significant findings in the subgroup analysis for the glycosylated hemoglobin (HbA1c) analyses. Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Weight at Week 0, Week 4, and 6-Month Endpoints</measure>
    <time_frame>Baseline (Week -1), Week 0, 4 weeks, 6 months</time_frame>
    <description>Values obtained from repeated measures analysis, which included the fixed categorical effects of treatment, baseline therapy strata (metformin versus diet and exercise [D&amp;E]), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline weight. Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Antibodies to LY2428757</measure>
    <time_frame>Baseline (Week -1) through 6 months</time_frame>
    <description>Participants who were positive for antibodies to LY2428757.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Antibodies to TT223</measure>
    <time_frame>Baseline (Week -1) through 6 months</time_frame>
    <description>Participants who were positive for antibodies for TT223.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PKs) of TT223, First Dose - Time of Maximum Observed Drug Concentration (Tmax)</measure>
    <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
    <description>Time of maximum observed drug concentration (Tmax) is the time at which the maximum observed concentration (Cmax) occurs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PKs) of TT223, First Dose - Maximum Observed Drug Concentration (Cmax)</measure>
    <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
    <description>Maximum observed drug concentration (Cmax) is the maximum observed concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PKs) of TT223, First Dose - Half-Life (t1/2) Associated With the Terminal Rate Constant (λz) in Non-Compartmental Analysis</measure>
    <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
    <description>Half-life is the time it takes for the concentration of drug in plasma to decline by 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PKs) of TT223, First Dose - Area Under the Curve (AUC)(0-infinity)</measure>
    <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
    <description>Area under the curve (AUC)(0-infinity) = area under concentration versus time from zero to infinity. Area under the curve (AUC) is a measure of the total exposure to a drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PKs) of TT223, First Dose - Apparent Total Body Clearance of Drug Calculated After Extra-Vascular Administration (CL/F)</measure>
    <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
    <description>Apparent total body clearance of drug calculated after extra-Vascular administration (CL/F) is the apparent volume of the body fluid cleared of the drug per unit of time, adjusted for how much drug goes into the body fluid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PKs) of TT223, First Dose - Apparent Volume of Distribution During the Terminal Phase After Extra-Vascular Administration (Vz/F), Apparent Volume of Distribution at Steady-State After Extra-Vascular Administration (Vss/F)</measure>
    <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
    <description>volume of distribution during the terminal phase after extra-vascular administration (Vz/F): Apparent volume that contains drug after absorption is complete and drug is no longer being given. Apparent volume of distribution at steady-State after extra-vascular administration (Vss/F): Apparent volume that contains drug when drug is being given continuously.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PKs) of TT223, 3-Week Time Point - Maximum Observed Drug Concentration (Cmax)</measure>
    <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
    <description>Maximum observed drug concentration (Cmax) is the maximum observed concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PKs) of TT223, 3-Week Time Point - Time of Maximum Observed Drug Concentration (Tmax)</measure>
    <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
    <description>Time of maximum observed drug concentration (Tmax) is the time at which the maximum observed concentration (Cmax) occurs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PKs) of TT223, 3-Week Time Point - Half Life (t1/2)</measure>
    <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
    <description>Half-life (t1/2) is the time it takes for the concentration of drug in plasma to decline by 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PKs) of TT223, 3-Week Time Point - Area Under Concentration Versus Time From Zero to Infinity (AUC[0-infinity])</measure>
    <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
    <description>Area under concentration versus time curve from zero to infinity (AUC[0-infinity]). Area under the curve (AUC) is a measure of the total exposure to a drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PKs) of TT223, 3-Week Time Point - Apparent Total Body Clearance of Drug Calculated After Extra-Vascular Administration (CL/F)</measure>
    <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
    <description>Apparent total body clearance of drug calculated after extra-vascular administration (CL/F) is the apparent volume of the body fluid cleared of the drug per unit of time, adjusted for how much drug goes into the body fluid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PKs) of TT223, 3-Week Time Point - Apparent Volume of Distribution During the Terminal Phase After Extra-Vascular Administration (Vz/F), Apparent Volume of Distribution at Steady-State After Extra-Vascular Administration (Vss/F)</measure>
    <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
    <description>Apparent volume of distribution during the terminal phase after extra-vascular administration (Vz/F) is the apparent volume that contains drug after absorption is complete and drug is no longer being given. Apparent volume of distribution at steady-state after extra-vascular administration (Vss/F) is the apparent volume that contains drug when drug is being given continuously.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PKs) of LY2428757, 3-Week Time Point - Maximum Observed Drug Concentration (Cmax)</measure>
    <time_frame>0 (pre-dose)</time_frame>
    <description>Maximum observed drug concentration (Cmax) is the maximum observed concentration of drug. LY2428757 concentrations were collected at only a single timepoint; therefore, pharmacokinetic (PK) parameters could not be modeled from the data. Analysis was not done due to insufficient time points being collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) for Nausea</measure>
    <time_frame>4 weeks, 6 months</time_frame>
    <description>The Visual Analog Scale (VAS) is a continuous measure for degree of nausea and/or gastrointestinal discomfort. Each of these scales is 100 millimeters (mm) in length with 0 meaning no nausea at all and 100 meaning extreme nausea. Participants record self-assessment of how much nausea they have had, from 0 to 100, during the time interval indicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Waist Circumference at 6-Month Endpoint</measure>
    <time_frame>Baseline (Week -1), 6 months</time_frame>
    <description>Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-point Profile, Self-Monitored Blood Glucose (SMBG) Values</measure>
    <time_frame>Baseline (Week -1), 4 weeks, 6 months</time_frame>
    <description>The 7-point average is the average of the mean value of all time points for the visit. Time points included pre-morning meal, 2 hours after morning meal, pre-midday meal, 2 hours after midday meal, pre-evening meal, 2 hours after evening meal, and bedtime.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 7-Point Profile, Self-Monitored Blood Glucose (SMBG) at 4-Week and 6-Month Endpoints</measure>
    <time_frame>Baseline (Week -1), 4 weeks, 6 months</time_frame>
    <description>7-point average=average of mean value of all time points for visit (premorning meal, 2-hours postmorning meal, premidday meal, 2-hours postmidday meal, preevening meal, 2-hours postevening meal, bedtime). Values represent mean of values collected same time on 3 separate days within week prior to visit. Values from repeated measures included fixed categorical effects: treatment, baseline therapy strata, visit, treatment-by-visit, continuous fixed covariate baseline &lt;7-point average glucose value or time point presented. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lipase at Week 0, Week 4, and 6-Month Endpoints</measure>
    <time_frame>Baseline (Week -1), Week 0, 4 weeks, 6 months</time_frame>
    <description>Values obtained from repeated measures analysis, which included the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline serum lipase. Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Amylase at 6-Month Endpoint</measure>
    <time_frame>Baseline (Week -1), 6 months</time_frame>
    <description>Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With 2-Fold Elevation of Lipase and/or Amylase at Any Timepoint</measure>
    <time_frame>Baseline (Week -1) through 6 months</time_frame>
    <description>Values obtained from repeated measures analysis, which included the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline amylase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hypoglycemia</measure>
    <time_frame>Baseline (Week -1) through 6 months</time_frame>
    <description>Calculation of frequency of low glucose for time period. Hypoglycemia≥1 events: severe&lt;50mg/dL, unable to treat self/recover after treatment; documented symptomatic≤70mg/dL, adrenergic/neuroglycopenic symptoms; asymptomatic≤70mg/dL no symptoms; probable symptomatic glucose missing, adrenergic/neuroglycopenic symptoms; relative&gt;70mg/dL, adrenergic/neuroglycopenic symptoms, nocturnal≤70mg/dL, adrenergic/neuroglycopenic symptoms between bedtime/waking. Because number participants who experienced hypoglycemia was low for every arm (1-3/arm) did not model percentage participants with hypoglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hypoglycemia</measure>
    <time_frame>Baseline (Week -1) through 6 months</time_frame>
    <description>The number of participants for whom low blood glucose was reported. Hypoglycemia ≥1 events including: severe hypoglycemia(glucose &lt;50mg/dL, unable to treat self or recover after treatment); documented symptomatic (glucose ≤70mg/dL, adrenergic or neuroglycopenic symptoms); asymptomatic (glucose ≤70mg/dL no symptoms); probable symptomatic (glucose missing, adrenergic or neuroglycopenic symptoms); relative (glucose &gt;70mg/dL, adrenergic or neuroglycopenic symptoms), nocturnal (glucose ≤70mg/dL, adrenergic or neuroglycopenic symptoms between bedtime/waking).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adjudicated and Confirmed Deaths and Non-Fatal Cardiovascular (CV) Events at Any Timepoint</measure>
    <time_frame>Baseline (Week -1) through 6 months</time_frame>
    <description>The protocol specified that deaths and nonfatal cardiovascular (CV) adverse events (AEs) be adjudicated by independent physician(s) with cardiology or neurology experience. The CV AEs to be adjudicated were protocol-defined as myocardial infarction (MI), hospitalization for unstable angina or for heart failure, coronary interventions (coronary artery bypass graft or percutaneous coronary intervention [PCI]) and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack (TIA). 3 CV events were adjudicated by an external independent adjudication committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Insulin at 4-Week and 6-Month Endpoints</measure>
    <time_frame>Baseline (Week -1), 4 weeks, 6 months</time_frame>
    <description>Values obtained from repeated measures analysis, which included the fixed categorical effects of treatment, baseline therapy strata (metformin versus diet and exercise [D&amp;E]), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline Fasting Insulin. Fasting insulin is the Mixed-Meal Tolerance Test (MMTT) insulin assessment at timepoint 0, where available, otherwise it is the assessment taken from the fasting laboratory measurements obtained during the clinic visit. Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Homeostatic Model Assessment (HOMA) at 3-Week and 6-Month Endpoints</measure>
    <time_frame>Baseline (Week -1), 3 weeks, 6 months</time_frame>
    <description>Values from repeated measures include fixed categorical effects of treatment, baseline therapy strata, visit, treatment-by-visit, continuous fixed covariate of baseline HOMA derived beta-cell function (HOMA-B). HOMA=index of function of cells that make insulin. Indices derived from fasting glucose and insulin concentrations. HOMA is measurement reflecting fasting plasma glucose and insulin. Has no defined minimum/maximum value. HOMA-B values generated from table reflecting values derived from Oxford HOMA2 model calculator. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>LY2428757 plus TT223 3 milligrams (mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly LY2428757 plus 3 milligrams (mg) daily TT223</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2428757 plus TT223 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly LY2428757 plus 2 mg daily TT223</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2428757 plus placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly LY2428757 plus daily TT223 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Weekly LY2428757 placebo plus daily TT223 placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2428757</intervention_name>
    <description>14 mg subcutaneous injection 1 time a week for 5 weeks</description>
    <arm_group_label>LY2428757 plus TT223 3 milligrams (mg)</arm_group_label>
    <arm_group_label>LY2428757 plus TT223 2mg</arm_group_label>
    <arm_group_label>LY2428757 plus placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TT223</intervention_name>
    <description>subcutaneous injection once a day for 4 weeks</description>
    <arm_group_label>LY2428757 plus TT223 3 milligrams (mg)</arm_group_label>
    <arm_group_label>LY2428757 plus TT223 2mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for LY2428757</intervention_name>
    <description>subcutaneous injection 1 time a week for 5 weeks</description>
    <arm_group_label>Placebo plus Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for TT223</intervention_name>
    <description>subcutaneous injection once a day for 4 weeks</description>
    <arm_group_label>LY2428757 plus placebo</arm_group_label>
    <arm_group_label>Placebo plus Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Have type 2 diabetes mellitus (T2DM) for at least 6 months

          -  Currently treated with diet and exercise alone or in combination with stable metformin

          -  Glycosylated hemoglobin (HbA1c) 7.0% to 10.0%

          -  Ages 18 to 70 years

          -  Women not of childbearing potential

          -  Body mass index (BMI) between 25 and 40 kilograms per meters squared (kg/m^2), and
             stable weight in the 3 months prior to screening.

        Exclusion Criteria:

          -  Use of diabetes medicine other than metformin in past 3 months

          -  Gastrointestinal disease or surgery or drugs that significantly impacts gastric
             filling, emptying or motility; ongoing cholelithiasis or cholecystitis.

          -  Chronic, daily proton pump inhibitors (PPIs) and histamine (H2) antagonists.

          -  Severe hypoglycemia or hyperglycemia

          -  Advanced microvascular diabetes complications

          -  Medications to promote weight loss.

          -  Breastfeeding women

          -  Cardiac autonomic neuropathy

          -  In the past 6 months have cardiac disease with functional status that is Class II-IV
             or a history of myocardial infarction, unstable angina, coronary artery bypass graft,
             percutaneous coronary intervention, transient ischemic attack, cerebrovascular
             accident (stroke), or decompensated congestive heart failure.

          -  History of a supraventricular or ventricular tachycardia, pacemaker implantation, or
             other cardiac arrhythmia: Poorly controlled hypertension, malignant hypertension,
             renal artery stenosis, and/or evidence of labile blood pressure including symptomatic
             postural hypotension.

          -  Electrocardiograms (ECG) abnormality or medication that impairs the ability to measure
             QT interval (QT), or correct the QT interval (QT) for rate.

          -  QT interval Bazett corrected (QTcB) &gt;450 milliseconds (msec) or PR interval (PR) &gt;220
             milliseconds (msec)

          -  Personal or family history of long QT interval (QT) syndrome, sudden death, or
             unexplained syncope

          -  Clinical signs or symptoms of liver disease, acute or chronic hepatitis, or alanine
             transaminase levels &gt; 2.5 times the upper limit of the reference range

          -  Hypertriglyceridemia &gt; 400 mg/deciliter (dL)

          -  Inadequately treated hypothyroidism or hyperthyroidism

          -  Peptic ulcer disease and/or gastrointestinal bleeding/perforation.

          -  Known pentagastrin hypersensitivity

          -  Impaired renal function

          -  Transplanted organ.

          -  Active, uncontrolled endocrine or autoimmune abnormality

          -  &gt; 2 weeks systemic glucocorticoid therapy

          -  Ongoing courses of non-steroidal anti-inflammatory drugs (NSAIDs), except for aspirin
             81-325 milligrams (mg)

          -  Diagnosed malignancy or in remission for less than 5 years.

          -  Prior acute or chronic pancreatitis or elevated serum lipase or amylase

          -  Current central nervous system stimulant

          -  Other conditions that preclude the participant from participating, following or
             completing the protocol.

          -  Chronic infection

          -  Personnel affiliated with the study and their immediate families.

          -  Within 30 days of the initial dose of study drug, have participated in an
             interventional medical, surgical, or pharmaceutical study in which a medical or
             surgical treatment was given.

          -  Have previously completed or withdrawn from this study after providing informed
             consent.

          -  Are currently enrolled in, or discontinued within the last 30 days from, a clinical
             trial involving an off-label use of an investigational drug or device (other than the
             study drug/device used in this study), or concurrently enrolled in any other type of
             medical research judged not to be scientifically or medically compatible with this
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT -5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <zip>90701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Norwalk</city>
        <state>California</state>
        <zip>90650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Elizabeth</city>
        <state>New Jersey</state>
        <zip>07202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Yukon</city>
        <state>Oklahoma</state>
        <zip>73099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taylors</city>
        <state>South Carolina</state>
        <zip>29687</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Midvale</city>
        <state>Utah</state>
        <zip>84047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Carolina</city>
        <zip>00983</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Manati</city>
        <zip>00674</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Juan</city>
        <zip>00907</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2009</study_first_submitted>
  <study_first_submitted_qc>February 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2009</study_first_posted>
  <results_first_submitted>September 15, 2011</results_first_submitted>
  <results_first_submitted_qc>March 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 13, 2012</results_first_posted>
  <last_update_submitted>March 19, 2012</last_update_submitted>
  <last_update_submitted_qc>March 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Reporting on 131 participants who received either TT223 or its placebo and reflects data from treatment and follow-up. 151 enrolled in run-in. 16/130 randomized to LY2428757 run-in did not get treatment assignment. 3/21 assigned to placebo run-in did not enter treatment phase. 1 was given treatment assignment but never received TT223 or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LY2428757 Plus TT223 3mg</title>
          <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>LY2428757 Plus TT223 2mg</title>
          <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>LY2428757 Plus TT223 Placebo</title>
          <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
        </group>
        <group group_id="P4">
          <title>LY Placebo Plus TT223 Placebo</title>
          <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion/Exclusion Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LY2428757 Plus TT223 3mg</title>
          <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>LY2428757 Plus TT223 2mg</title>
          <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>LY2428757 Plus TT223 Placebo</title>
          <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
        </group>
        <group group_id="B4">
          <title>LY Placebo Plus TT223 Placebo</title>
          <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="38"/>
            <count group_id="B4" value="18"/>
            <count group_id="B5" value="131"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.7" spread="9.69"/>
                    <measurement group_id="B2" value="52.4" spread="10.12"/>
                    <measurement group_id="B3" value="52.9" spread="8.99"/>
                    <measurement group_id="B4" value="55.4" spread="7.90"/>
                    <measurement group_id="B5" value="53.3" spread="9.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 6-Month Endpoint</title>
        <description>Values obtained from repeated measures analysis, which included the fixed categorical effects of treatment, baseline therapy strata (metformin versus diet and exercise [D&amp;E]), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline glycosylated hemoglobin (HbA1c). Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
        <time_frame>Baseline (Week -1), 6 months</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline glycosylated hemoglobin (HbA1c) value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 6-Month Endpoint</title>
          <description>Values obtained from repeated measures analysis, which included the fixed categorical effects of treatment, baseline therapy strata (metformin versus diet and exercise [D&amp;E]), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline glycosylated hemoglobin (HbA1c). Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline glycosylated hemoglobin (HbA1c) value.</population>
          <units>percent glycosylated hemoglobin (HbA1c)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.163"/>
                    <measurement group_id="O2" value="0.06" spread="0.179"/>
                    <measurement group_id="O3" value="-0.15" spread="0.162"/>
                    <measurement group_id="O4" value="0.04" spread="0.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.623</p_value>
            <p_value_desc>p-value is for LY2428757 plus TT223 3 mg versus LY2428757 plus TT223 placebo.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Model included treatment, baseline therapy, strata, visit, and treatment-by-visit interaction, and continuous fixed covariate of baseline HbA1c.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.809</p_value>
            <p_value_desc>p-value is for LY2428757 plus TT223 2 mg versus LY2428757 plus TT223 placebo.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Model included treatment, baseline therapy, strata, visit, and treatment-by-visit interaction, and continuous fixed covariate of baseline HbA1c.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 4-Week Endpoint</title>
        <description>Values obtained from repeated measures analysis, which included the fixed categorical effects of treatment, baseline therapy strata (metformin versus diet and exercise [D&amp;E]), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline glycosylated hemoglobin (HbA1c). Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
        <time_frame>Baseline (Week -1), 4 weeks</time_frame>
        <population>Intent-to-treat (ITT): All participants who received at least 1 dose of TT223 or its placebo with a baseline and at least 1 post-baseline glycosylated hemoglobin (HbA1c) value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 4-Week Endpoint</title>
          <description>Values obtained from repeated measures analysis, which included the fixed categorical effects of treatment, baseline therapy strata (metformin versus diet and exercise [D&amp;E]), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline glycosylated hemoglobin (HbA1c). Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
          <population>Intent-to-treat (ITT): All participants who received at least 1 dose of TT223 or its placebo with a baseline and at least 1 post-baseline glycosylated hemoglobin (HbA1c) value.</population>
          <units>percent glycosylated hemoglobin (HbA1c)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="0.111"/>
                    <measurement group_id="O2" value="-0.97" spread="0.117"/>
                    <measurement group_id="O3" value="-0.79" spread="0.112"/>
                    <measurement group_id="O4" value="-0.19" spread="0.162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mixed-Meal Tolerance Test (MMTT) Response - Glucose Area Under the Curve (AUC) at 3-Week and 6-Month Endpoints</title>
        <description>Standardized mixed-meal tolerance test (MMTT) used to assess changes in function of cells that make insulin (pancreatic beta cell function). Area under the plasma glucose concentration versus time curve calculated using linear-trapezoidal method. AUC for glucose represents area under curve of values when plotted over time. Larger area under the curve values represent greater average glucose value over time in response to meal. Least squares (LS) means adjusted for baseline, treatment, visit, treatment-by-visit. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
        <time_frame>Baseline (Week -1), 3 weeks, 6 months</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline value and at least 1 post-baseline glucose area under the curve (AUC) value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mixed-Meal Tolerance Test (MMTT) Response - Glucose Area Under the Curve (AUC) at 3-Week and 6-Month Endpoints</title>
          <description>Standardized mixed-meal tolerance test (MMTT) used to assess changes in function of cells that make insulin (pancreatic beta cell function). Area under the plasma glucose concentration versus time curve calculated using linear-trapezoidal method. AUC for glucose represents area under curve of values when plotted over time. Larger area under the curve values represent greater average glucose value over time in response to meal. Least squares (LS) means adjusted for baseline, treatment, visit, treatment-by-visit. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline value and at least 1 post-baseline glucose area under the curve (AUC) value.</population>
          <units>millimoles/liter*hour (mmol/L*hr)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Weeks (n=32, 27, 32, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.04" spread="2.121"/>
                    <measurement group_id="O2" value="13.14" spread="2.300"/>
                    <measurement group_id="O3" value="7.51" spread="2.138"/>
                    <measurement group_id="O4" value="28.47" spread="2.979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months (n=23, 21, 22, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.21" spread="1.490"/>
                    <measurement group_id="O2" value="-1.05" spread="1.622"/>
                    <measurement group_id="O3" value="-1.05" spread="1.549"/>
                    <measurement group_id="O4" value="1.46" spread="2.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mixed-Meal Tolerance Test (MMTT) Response - C-Peptide Area Under the Curve (AUC) at 3-Week and 6-Month Endpoints</title>
        <description>The area under the C-peptide concentration versus time curve was calculated using the linear-trapezoidal method. Area under the curve (AUC) for C-peptide represents area under the curve (AUC) of C-peptide values when plotted over time. Larger area under the curve (AUC) values represent a greater average C-peptide value over time in response to a meal. Least squares (LS) means adjusted for baseline, treatment, visit, treatment-by-visit interaction. Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
        <time_frame>Baseline (Week -1), 3 weeks, 6 months</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline C-peptide area under the curve (AUC) value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mixed-Meal Tolerance Test (MMTT) Response - C-Peptide Area Under the Curve (AUC) at 3-Week and 6-Month Endpoints</title>
          <description>The area under the C-peptide concentration versus time curve was calculated using the linear-trapezoidal method. Area under the curve (AUC) for C-peptide represents area under the curve (AUC) of C-peptide values when plotted over time. Larger area under the curve (AUC) values represent a greater average C-peptide value over time in response to a meal. Least squares (LS) means adjusted for baseline, treatment, visit, treatment-by-visit interaction. Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline C-peptide area under the curve (AUC) value.</population>
          <units>millimoles/liter*hour (mmol/L*hr)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Weeks (n=32, 28, 32, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.44" spread="163.317"/>
                    <measurement group_id="O2" value="-44.12" spread="176.487"/>
                    <measurement group_id="O3" value="119.23" spread="164.846"/>
                    <measurement group_id="O4" value="-24.89" spread="226.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months (n=23, 21, 22, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221.02" spread="185.341"/>
                    <measurement group_id="O2" value="-148.34" spread="197.247"/>
                    <measurement group_id="O3" value="-241.88" spread="190.870"/>
                    <measurement group_id="O4" value="-133.30" spread="253.264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mixed Meal Tolerance Test (MMTT) Response - Ratio of Insulin Area Under the Curve (AUC)/Glucose Area Under the Curve (AUC) at 3-Week and 6-Month Endpoints</title>
        <description>Mixed meal tolerance test (MMTT) to assess changes in function of cells making insulin. AUCinsulin/AUCglucose ratio: index of insulin secretion. Larger values reflect greater secretion adjusted for glucose in response to meal. Area under insulin concentration versus time curve and area under plasma glucose concentration versus time curve calculated using linear-trapezoidal method. AUC for insulin and glucose represents AUC of values plotted over time. LS means adjusted for baseline, treatment, visit, treatment-by-visit. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
        <time_frame>Baseline (Week -1), 3 weeks, 6 months</time_frame>
        <population>Intent-to-treat population (ITT): All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline AUC insulin/AUC glucose value. Reporting is on the 131 participants who received either TT223 or its placebo and reflects data only from the treatment and follow-up phases of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mixed Meal Tolerance Test (MMTT) Response - Ratio of Insulin Area Under the Curve (AUC)/Glucose Area Under the Curve (AUC) at 3-Week and 6-Month Endpoints</title>
          <description>Mixed meal tolerance test (MMTT) to assess changes in function of cells making insulin. AUCinsulin/AUCglucose ratio: index of insulin secretion. Larger values reflect greater secretion adjusted for glucose in response to meal. Area under insulin concentration versus time curve and area under plasma glucose concentration versus time curve calculated using linear-trapezoidal method. AUC for insulin and glucose represents AUC of values plotted over time. LS means adjusted for baseline, treatment, visit, treatment-by-visit. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
          <population>Intent-to-treat population (ITT): All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline AUC insulin/AUC glucose value. Reporting is on the 131 participants who received either TT223 or its placebo and reflects data only from the treatment and follow-up phases of the study.</population>
          <units>millimoles/liter*hour (mmol/L*hr)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Weeks (n=30, 27, 32, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="0.324"/>
                    <measurement group_id="O2" value="-0.90" spread="0.341"/>
                    <measurement group_id="O3" value="-0.16" spread="0.321"/>
                    <measurement group_id="O4" value="-1.37" spread="0.433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months (n=23, 21, 22, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.413"/>
                    <measurement group_id="O2" value="-0.19" spread="0.425"/>
                    <measurement group_id="O3" value="0.15" spread="0.418"/>
                    <measurement group_id="O4" value="-0.53" spread="0.566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mixed-Meal Tolerance Test (MMTT) Response - Glucagon Area Under the Curve (AUC) at 3-Week and 6-Month Endpoints</title>
        <description>Standardized mixed meal tolerance test (MMTT) to assess changes in hormones in response to meal. Area under the plasma glucagon concentration versus time curve was calculated using the linear-trapezoidal method. Area under the curve (AUC) for glucagon represents the AUC of glucagon values when are plotted over time. Larger area under the curve (AUC) values represent a greater average glucagon value over time in response to a meal. Least squares (LS) means adjusted for baseline, treatment, visit, treatment-by-visit. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
        <time_frame>Baseline (Week -1), 3 weeks, 6 months</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a value at Week -1 and a value at that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mixed-Meal Tolerance Test (MMTT) Response - Glucagon Area Under the Curve (AUC) at 3-Week and 6-Month Endpoints</title>
          <description>Standardized mixed meal tolerance test (MMTT) to assess changes in hormones in response to meal. Area under the plasma glucagon concentration versus time curve was calculated using the linear-trapezoidal method. Area under the curve (AUC) for glucagon represents the AUC of glucagon values when are plotted over time. Larger area under the curve (AUC) values represent a greater average glucagon value over time in response to a meal. Least squares (LS) means adjusted for baseline, treatment, visit, treatment-by-visit. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a value at Week -1 and a value at that visit.</population>
          <units>picomoles/liter (pmmol/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Weeks (n=30, 28, 32, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.76" spread="15.367"/>
                    <measurement group_id="O2" value="-29.12" spread="15.888"/>
                    <measurement group_id="O3" value="-47.76" spread="14.890"/>
                    <measurement group_id="O4" value="-26.46" spread="21.164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months (n=23, 21, 22, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.48" spread="4.504"/>
                    <measurement group_id="O2" value="-15.96" spread="4.810"/>
                    <measurement group_id="O3" value="-21.77" spread="4.654"/>
                    <measurement group_id="O4" value="-12.10" spread="6.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mixed-Meal Tolerance Test (MMTT) Response - Glucagon-like Peptide-1 (GLP-1) Area Under the Cure (AUC) at 3-Week and 6-Month Endpoints</title>
        <description>Standardized mixed meal tolerance test (MMTT) to assess changes in hormones in response to meal. Area under plasma glucagon-like peptide-1 (GLP-1) concentration versus time curve calculated using linear-trapezoidal method. Area under the curve (AUC) for glucagon-like peptide-1 (GLP-1) represents the AUC of GLP-1 values when plotted over time. Larger AUC values represent a greater average GLP-1 value over time in response to meal. Least squares (LS) means adjusted for baseline, treatment, visit, treatment-by-visit. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
        <time_frame>Baseline (Week -1), 3 weeks, 6 months</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a value at Week -1 and a value at that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mixed-Meal Tolerance Test (MMTT) Response - Glucagon-like Peptide-1 (GLP-1) Area Under the Cure (AUC) at 3-Week and 6-Month Endpoints</title>
          <description>Standardized mixed meal tolerance test (MMTT) to assess changes in hormones in response to meal. Area under plasma glucagon-like peptide-1 (GLP-1) concentration versus time curve calculated using linear-trapezoidal method. Area under the curve (AUC) for glucagon-like peptide-1 (GLP-1) represents the AUC of GLP-1 values when plotted over time. Larger AUC values represent a greater average GLP-1 value over time in response to meal. Least squares (LS) means adjusted for baseline, treatment, visit, treatment-by-visit. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a value at Week -1 and a value at that visit.</population>
          <units>picomoles/liter (pmmol/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Weeks (n=30, 28, 32, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.90" spread="2.007"/>
                    <measurement group_id="O2" value="0.86" spread="2.094"/>
                    <measurement group_id="O3" value="1.48" spread="1.948"/>
                    <measurement group_id="O4" value="-0.47" spread="2.702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months (n=23, 21, 22, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="2.162"/>
                    <measurement group_id="O2" value="0.51" spread="2.302"/>
                    <measurement group_id="O3" value="-5.93" spread="2.225"/>
                    <measurement group_id="O4" value="1.71" spread="2.955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mixed-Meal Tolerance Test (MMTT) Response - Post-Prandial Glucose at 3-Week and 6-Month Endpoints</title>
        <description>Standardized MMTT to assess changes in function of cells that make insulin (pancreatic beta cells). Glucose measured at 2-hour timepoint during MMTT reflects glucose values in response to meal. Change in postprandial glucose calculated based on difference of 2-hour postprandial glucose at endpoint compared to baseline. Larger changes from baseline represent a greater postprandial glucose compared to 2-hour timepoint prior to treatment. Least squares (LS) means adjusted for baseline, treatment, visit, treatment-by-visit. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
        <time_frame>Baseline (Week -1), 3 weeks, 6 months</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a value at Week -1 and a value at that visit and time point being assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mixed-Meal Tolerance Test (MMTT) Response - Post-Prandial Glucose at 3-Week and 6-Month Endpoints</title>
          <description>Standardized MMTT to assess changes in function of cells that make insulin (pancreatic beta cells). Glucose measured at 2-hour timepoint during MMTT reflects glucose values in response to meal. Change in postprandial glucose calculated based on difference of 2-hour postprandial glucose at endpoint compared to baseline. Larger changes from baseline represent a greater postprandial glucose compared to 2-hour timepoint prior to treatment. Least squares (LS) means adjusted for baseline, treatment, visit, treatment-by-visit. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a value at Week -1 and a value at that visit and time point being assessed.</population>
          <units>millimoles/liter (mmol/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Weeks 2 hours (n=32, 27, 31, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="0.417"/>
                    <measurement group_id="O2" value="-1.12" spread="0.455"/>
                    <measurement group_id="O3" value="-2.90" spread="0.426"/>
                    <measurement group_id="O4" value="0.60" spread="0.581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months 2 hours (n=23, 21, 22, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.541"/>
                    <measurement group_id="O2" value="-0.06" spread="0.576"/>
                    <measurement group_id="O3" value="-0.43" spread="0.556"/>
                    <measurement group_id="O4" value="0.58" spread="0.748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Blood Glucose (FBG) at 4-Week and 6-Month Endpoints</title>
        <description>Values obtained from repeated measures analysis, which included the fixed categorical effects of treatment, baseline therapy strata (metformin versus diet and exercise [D&amp;E]), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline fasting blood glucose (FBG). Fasting blood glucose (FBG) is the mixed meal tolerance test (MMTT) glucose assessment at time point 0, where available, otherwise it is the assessment taken from the chemistry panel. Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
        <time_frame>Baseline (Week -1), 4 weeks, 6 months</time_frame>
        <population>Intent-to-treat (ITT): All participants who received at least 1 dose of TT223 or its placebo with a baseline and at least 1 post-baseline fasting blood glucose (FBG) value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Blood Glucose (FBG) at 4-Week and 6-Month Endpoints</title>
          <description>Values obtained from repeated measures analysis, which included the fixed categorical effects of treatment, baseline therapy strata (metformin versus diet and exercise [D&amp;E]), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline fasting blood glucose (FBG). Fasting blood glucose (FBG) is the mixed meal tolerance test (MMTT) glucose assessment at time point 0, where available, otherwise it is the assessment taken from the chemistry panel. Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
          <population>Intent-to-treat (ITT): All participants who received at least 1 dose of TT223 or its placebo with a baseline and at least 1 post-baseline fasting blood glucose (FBG) value.</population>
          <units>millimoles per liter (mmol/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks (n=32, 27, 33, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.40"/>
                    <measurement group_id="O2" value="-1.6" spread="0.44"/>
                    <measurement group_id="O3" value="-1.6" spread="0.40"/>
                    <measurement group_id="O4" value="0.5" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=23, 21, 22, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.41"/>
                    <measurement group_id="O2" value="0.1" spread="0.44"/>
                    <measurement group_id="O3" value="0.3" spread="0.42"/>
                    <measurement group_id="O4" value="-0.2" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (HbA1C) Adjusted for Baseline Glycosylated Hemoglobin (HbA1c), C-Peptide Level, Homeostasis Model Assessment of Insulin Resistance (HOMA), Duration of Diabetes, and Body Mass Index (BMI) at 6-Month Endpoint</title>
        <description>HbA1c adjusted: baseline HbA1c (&lt;8%,≥8%); C-peptide level (normal, elevated); HOMA (&lt;baseline median,≥baseline median); duration diabetes (&lt;3,3-10,&gt;10 years); BMI (&lt;30,≥30). BMI estimates body fat based on weight/height squared. HOMA: index of function of cells that make insulin/insulin resistance. Indices derived from fasting glucose and insulin concentrations. LS means adjusted for treatment, baseline therapy, visit, treatment-by-visit, subgroup, subgroup-by-treatment, subgroup-by-visit, subgroup-by-treatment-by-visit. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
        <time_frame>Baseline (Week -1), 6 months</time_frame>
        <population>Intent-to-treat (ITT): All participants who received at least 1 dose of TT223 or its placebo with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (HbA1C) Adjusted for Baseline Glycosylated Hemoglobin (HbA1c), C-Peptide Level, Homeostasis Model Assessment of Insulin Resistance (HOMA), Duration of Diabetes, and Body Mass Index (BMI) at 6-Month Endpoint</title>
          <description>HbA1c adjusted: baseline HbA1c (&lt;8%,≥8%); C-peptide level (normal, elevated); HOMA (&lt;baseline median,≥baseline median); duration diabetes (&lt;3,3-10,&gt;10 years); BMI (&lt;30,≥30). BMI estimates body fat based on weight/height squared. HOMA: index of function of cells that make insulin/insulin resistance. Indices derived from fasting glucose and insulin concentrations. LS means adjusted for treatment, baseline therapy, visit, treatment-by-visit, subgroup, subgroup-by-treatment, subgroup-by-visit, subgroup-by-treatment-by-visit. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
          <population>Intent-to-treat (ITT): All participants who received at least 1 dose of TT223 or its placebo with a baseline and at least 1 post-baseline value.</population>
          <units>percent glucosylated hemoglobin (HbA1c)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline HbA1c &lt;8% (n=24, 21, 23, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.169"/>
                    <measurement group_id="O2" value="-0.22" spread="0.194"/>
                    <measurement group_id="O3" value="-0.20" spread="0.183"/>
                    <measurement group_id="O4" value="-0.53" spread="0.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline HbA1c &gt;=8% (n=24, 21, 23, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.250"/>
                    <measurement group_id="O2" value="0.40" spread="0.228"/>
                    <measurement group_id="O3" value="-0.12" spread="0.222"/>
                    <measurement group_id="O4" value="0.35" spread="0.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-peptide level normal (n=23, 21, 23, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="0.157"/>
                    <measurement group_id="O2" value="0.28" spread="0.165"/>
                    <measurement group_id="O3" value="-0.20" spread="0.140"/>
                    <measurement group_id="O4" value="-0.05" spread="0.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-peptide level elevated (n=23, 21, 23, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.254"/>
                    <measurement group_id="O2" value="-0.78" spread="0.286"/>
                    <measurement group_id="O3" value="0.06" spread="0.600"/>
                    <measurement group_id="O4" value="-0.32" spread="0.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HOMA &lt;baseline median (n=23, 19, 20, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.195"/>
                    <measurement group_id="O2" value="0.28" spread="0.241"/>
                    <measurement group_id="O3" value="-0.23" spread="0.209"/>
                    <measurement group_id="O4" value="0.16" spread="0.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HOMA &gt;=baseline median (n=23, 19, 20, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.187"/>
                    <measurement group_id="O2" value="-0.15" spread="0.188"/>
                    <measurement group_id="O3" value="-0.38" spread="0.195"/>
                    <measurement group_id="O4" value="-0.56" spread="0.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BMI &lt;30 (n=24, 21, 23, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.194"/>
                    <measurement group_id="O2" value="0.37" spread="0.250"/>
                    <measurement group_id="O3" value="0.07" spread="0.194"/>
                    <measurement group_id="O4" value="-0.34" spread="0.335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BMI &gt;=30 (n=24, 21, 23, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.179"/>
                    <measurement group_id="O2" value="-0.12" spread="0.172"/>
                    <measurement group_id="O3" value="-0.45" spread="0.189"/>
                    <measurement group_id="O4" value="0.03" spread="0.229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of diabetes &lt;3 years (n=24, 21, 23, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.87" spread="0.348"/>
                    <measurement group_id="O2" value="-0.77" spread="0.236"/>
                    <measurement group_id="O3" value="0.18" spread="0.240"/>
                    <measurement group_id="O4" value="-0.49" spread="0.263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration diabetes 3-&lt;10 years (n=24, 21, 23, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.157"/>
                    <measurement group_id="O2" value="0.50" spread="0.192"/>
                    <measurement group_id="O3" value="-0.34" spread="0.172"/>
                    <measurement group_id="O4" value="0.49" spread="0.307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of diabetes &gt;=10 years (n=24, 21, 23, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.278"/>
                    <measurement group_id="O2" value="0.09" spread="0.349"/>
                    <measurement group_id="O3" value="-0.50" spread="0.429"/>
                    <measurement group_id="O4" value="-0.28" spread="0.425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in MMTT Response (Postprandial Glucose, Glucose AUC, Insulin/c-Peptide Secretory Response, HOMA, GLP-1, Glucagon) Adjusted for Baseline HbA1c, C-Peptide Level, HOMA, Duration of Diabetes, Weight at Week 0, 3, Month 3.5, 6 Endpoints</title>
        <description>Subgroup analyses for mixed meal tolerance test (MMTT) response (adjusted for baseline glycosylated hemoglobin (HbA1c), C-peptide level, Homeostasis Model Assessment of Insulin Resistance (HOMA), duration of diabetes, weight) not performed due to lack of statistically significant findings in subgroup analysis for HbA1c analyses. HOMA was not done for mixed meal tolerance test (MMTT) because it is not calculated from the mixed meal tolerance test (MMTT). It is reported separately as a secondary outcome measure. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
        <time_frame>Baseline (Week -1), Week 0, 3 weeks, 3.5 months, 6 months</time_frame>
        <population>Because the subgroup analyses for MMTT response were not conducted due to the lack of statistically significant findings in the subgroup analysis for the HbA1c analyses, zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in MMTT Response (Postprandial Glucose, Glucose AUC, Insulin/c-Peptide Secretory Response, HOMA, GLP-1, Glucagon) Adjusted for Baseline HbA1c, C-Peptide Level, HOMA, Duration of Diabetes, Weight at Week 0, 3, Month 3.5, 6 Endpoints</title>
          <description>Subgroup analyses for mixed meal tolerance test (MMTT) response (adjusted for baseline glycosylated hemoglobin (HbA1c), C-peptide level, Homeostasis Model Assessment of Insulin Resistance (HOMA), duration of diabetes, weight) not performed due to lack of statistically significant findings in subgroup analysis for HbA1c analyses. HOMA was not done for mixed meal tolerance test (MMTT) because it is not calculated from the mixed meal tolerance test (MMTT). It is reported separately as a secondary outcome measure. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
          <population>Because the subgroup analyses for MMTT response were not conducted due to the lack of statistically significant findings in the subgroup analysis for the HbA1c analyses, zero participants were analyzed.</population>
          <units>millimoles per liter (mmol/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Blood Glucose (FBG) Adjusted for Baseline HbA1c, C-Peptide Level, Homeostasis Model Assessment of Insulin Resistance, Duration of Diabetes, and Weight at 3-Week, 4-Week, 2-Month, 3.5-Month, 5-Month, and 6-Month Endpoints</title>
        <description>The subgroup analyses for fasting blood glucose (FBG) (adjusted for baseline glycosylated hemoglobin [HbA1c]), C-peptide level, homeostasis model assessment of insulin resistance (HOMA), duration of diabetes, and weight) were not performed due to the lack of statistically significant findings in the subgroup analysis for the glycosylated hemoglobin (HbA1c) analyses. Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
        <time_frame>Baseline (Week -1), 3 weeks, 4 weeks, 2 months, 3.5 months, 5 months, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Blood Glucose (FBG) Adjusted for Baseline HbA1c, C-Peptide Level, Homeostasis Model Assessment of Insulin Resistance, Duration of Diabetes, and Weight at 3-Week, 4-Week, 2-Month, 3.5-Month, 5-Month, and 6-Month Endpoints</title>
          <description>The subgroup analyses for fasting blood glucose (FBG) (adjusted for baseline glycosylated hemoglobin [HbA1c]), C-peptide level, homeostasis model assessment of insulin resistance (HOMA), duration of diabetes, and weight) were not performed due to the lack of statistically significant findings in the subgroup analysis for the glycosylated hemoglobin (HbA1c) analyses. Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
          <units>millimoles per liter (mmol/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Weight at Week 0, Week 4, and 6-Month Endpoints</title>
        <description>Values obtained from repeated measures analysis, which included the fixed categorical effects of treatment, baseline therapy strata (metformin versus diet and exercise [D&amp;E]), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline weight. Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
        <time_frame>Baseline (Week -1), Week 0, 4 weeks, 6 months</time_frame>
        <population>Intent-to-treat (ITT): All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline weight value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Weight at Week 0, Week 4, and 6-Month Endpoints</title>
          <description>Values obtained from repeated measures analysis, which included the fixed categorical effects of treatment, baseline therapy strata (metformin versus diet and exercise [D&amp;E]), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline weight. Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
          <population>Intent-to-treat (ITT): All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline weight value.</population>
          <units>kilograms (kg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=38, 37, 38, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.198" spread="0.2380"/>
                    <measurement group_id="O2" value="-0.137" spread="0.2455"/>
                    <measurement group_id="O3" value="-0.288" spread="0.2438"/>
                    <measurement group_id="O4" value="0.305" spread="0.3338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks (n=33, 27, 33, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.561" spread="0.2923"/>
                    <measurement group_id="O2" value="-0.975" spread="0.3167"/>
                    <measurement group_id="O3" value="-0.824" spread="0.2956"/>
                    <measurement group_id="O4" value="-0.542" spread="0.4090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=24, 21, 23,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.066" spread="0.7007"/>
                    <measurement group_id="O2" value="0.026" spread="0.7613"/>
                    <measurement group_id="O3" value="-0.762" spread="0.7044"/>
                    <measurement group_id="O4" value="-0.164" spread="0.9996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Antibodies to LY2428757</title>
        <description>Participants who were positive for antibodies to LY2428757.</description>
        <time_frame>Baseline (Week -1) through 6 months</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Antibodies to LY2428757</title>
          <description>Participants who were positive for antibodies to LY2428757.</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Antibodies to TT223</title>
        <description>Participants who were positive for antibodies for TT223.</description>
        <time_frame>Baseline (Week -1) through 6 months</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Antibodies to TT223</title>
          <description>Participants who were positive for antibodies for TT223.</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PKs) of TT223, First Dose - Time of Maximum Observed Drug Concentration (Tmax)</title>
        <description>Time of maximum observed drug concentration (Tmax) is the time at which the maximum observed concentration (Cmax) occurs.</description>
        <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 2 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 3 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PKs) of TT223, First Dose - Time of Maximum Observed Drug Concentration (Tmax)</title>
          <description>Time of maximum observed drug concentration (Tmax) is the time at which the maximum observed concentration (Cmax) occurs.</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.30-3.00" lower_limit="0.30" upper_limit="3.00"/>
                    <measurement group_id="O2" value="1.00" spread="0.30-4.00" lower_limit="0.30" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PKs) of TT223, First Dose - Maximum Observed Drug Concentration (Cmax)</title>
        <description>Maximum observed drug concentration (Cmax) is the maximum observed concentration of drug.</description>
        <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 2 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 3 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PKs) of TT223, First Dose - Maximum Observed Drug Concentration (Cmax)</title>
          <description>Maximum observed drug concentration (Cmax) is the maximum observed concentration of drug.</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
          <units>nanograms per milliliter (ng/ml)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.52" spread="276"/>
                    <measurement group_id="O2" value="8.46" spread="531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PKs) of TT223, First Dose - Half-Life (t1/2) Associated With the Terminal Rate Constant (λz) in Non-Compartmental Analysis</title>
        <description>Half-life is the time it takes for the concentration of drug in plasma to decline by 50%.</description>
        <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 2 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 3 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PKs) of TT223, First Dose - Half-Life (t1/2) Associated With the Terminal Rate Constant (λz) in Non-Compartmental Analysis</title>
          <description>Half-life is the time it takes for the concentration of drug in plasma to decline by 50%.</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="56"/>
                    <measurement group_id="O2" value="1.20" spread="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PKs) of TT223, First Dose - Area Under the Curve (AUC)(0-infinity)</title>
        <description>Area under the curve (AUC)(0-infinity) = area under concentration versus time from zero to infinity. Area under the curve (AUC) is a measure of the total exposure to a drug.</description>
        <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 2 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 3 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PKs) of TT223, First Dose - Area Under the Curve (AUC)(0-infinity)</title>
          <description>Area under the curve (AUC)(0-infinity) = area under concentration versus time from zero to infinity. Area under the curve (AUC) is a measure of the total exposure to a drug.</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
          <units>nanograms*hour/milliliter (ng*hr/ml)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0" spread="66"/>
                    <measurement group_id="O2" value="52.2" spread="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PKs) of TT223, First Dose - Apparent Total Body Clearance of Drug Calculated After Extra-Vascular Administration (CL/F)</title>
        <description>Apparent total body clearance of drug calculated after extra-Vascular administration (CL/F) is the apparent volume of the body fluid cleared of the drug per unit of time, adjusted for how much drug goes into the body fluid.</description>
        <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 2 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 3 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks TT223</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PKs) of TT223, First Dose - Apparent Total Body Clearance of Drug Calculated After Extra-Vascular Administration (CL/F)</title>
          <description>Apparent total body clearance of drug calculated after extra-Vascular administration (CL/F) is the apparent volume of the body fluid cleared of the drug per unit of time, adjusted for how much drug goes into the body fluid.</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
          <units>liters/hour (L/hr)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" spread="66"/>
                    <measurement group_id="O2" value="57.5" spread="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PKs) of TT223, First Dose - Apparent Volume of Distribution During the Terminal Phase After Extra-Vascular Administration (Vz/F), Apparent Volume of Distribution at Steady-State After Extra-Vascular Administration (Vss/F)</title>
        <description>volume of distribution during the terminal phase after extra-vascular administration (Vz/F): Apparent volume that contains drug after absorption is complete and drug is no longer being given. Apparent volume of distribution at steady-State after extra-vascular administration (Vss/F): Apparent volume that contains drug when drug is being given continuously.</description>
        <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 2 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 3 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PKs) of TT223, First Dose - Apparent Volume of Distribution During the Terminal Phase After Extra-Vascular Administration (Vz/F), Apparent Volume of Distribution at Steady-State After Extra-Vascular Administration (Vss/F)</title>
          <description>volume of distribution during the terminal phase after extra-vascular administration (Vz/F): Apparent volume that contains drug after absorption is complete and drug is no longer being given. Apparent volume of distribution at steady-State after extra-vascular administration (Vss/F): Apparent volume that contains drug when drug is being given continuously.</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
          <units>liters (L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vz/F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115" spread="108"/>
                    <measurement group_id="O2" value="99.2" spread="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vss/F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157" spread="91"/>
                    <measurement group_id="O2" value="136" spread="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PKs) of TT223, 3-Week Time Point - Maximum Observed Drug Concentration (Cmax)</title>
        <description>Maximum observed drug concentration (Cmax) is the maximum observed concentration of drug.</description>
        <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 2 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 3 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PKs) of TT223, 3-Week Time Point - Maximum Observed Drug Concentration (Cmax)</title>
          <description>Maximum observed drug concentration (Cmax) is the maximum observed concentration of drug.</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
          <units>nanograms per milliliter (ng/ml)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.61" spread="652"/>
                    <measurement group_id="O2" value="5.97" spread="1320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PKs) of TT223, 3-Week Time Point - Time of Maximum Observed Drug Concentration (Tmax)</title>
        <description>Time of maximum observed drug concentration (Tmax) is the time at which the maximum observed concentration (Cmax) occurs.</description>
        <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 2 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 3 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PKs) of TT223, 3-Week Time Point - Time of Maximum Observed Drug Concentration (Tmax)</title>
          <description>Time of maximum observed drug concentration (Tmax) is the time at which the maximum observed concentration (Cmax) occurs.</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="0.33" upper_limit="6.00"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.32" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PKs) of TT223, 3-Week Time Point - Half Life (t1/2)</title>
        <description>Half-life (t1/2) is the time it takes for the concentration of drug in plasma to decline by 50%.</description>
        <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 2 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 3 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PKs) of TT223, 3-Week Time Point - Half Life (t1/2)</title>
          <description>Half-life (t1/2) is the time it takes for the concentration of drug in plasma to decline by 50%.</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="59"/>
                    <measurement group_id="O2" value="1.03" spread="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PKs) of TT223, 3-Week Time Point - Area Under Concentration Versus Time From Zero to Infinity (AUC[0-infinity])</title>
        <description>Area under concentration versus time curve from zero to infinity (AUC[0-infinity]). Area under the curve (AUC) is a measure of the total exposure to a drug.</description>
        <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 2 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 3 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PKs) of TT223, 3-Week Time Point - Area Under Concentration Versus Time From Zero to Infinity (AUC[0-infinity])</title>
          <description>Area under concentration versus time curve from zero to infinity (AUC[0-infinity]). Area under the curve (AUC) is a measure of the total exposure to a drug.</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
          <units>nanograms*hour/milliliter (ng*hr/ml)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1" spread="67"/>
                    <measurement group_id="O2" value="32.6" spread="596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PKs) of TT223, 3-Week Time Point - Apparent Total Body Clearance of Drug Calculated After Extra-Vascular Administration (CL/F)</title>
        <description>Apparent total body clearance of drug calculated after extra-vascular administration (CL/F) is the apparent volume of the body fluid cleared of the drug per unit of time, adjusted for how much drug goes into the body fluid.</description>
        <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 2 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 3 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks TT223</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PKs) of TT223, 3-Week Time Point - Apparent Total Body Clearance of Drug Calculated After Extra-Vascular Administration (CL/F)</title>
          <description>Apparent total body clearance of drug calculated after extra-vascular administration (CL/F) is the apparent volume of the body fluid cleared of the drug per unit of time, adjusted for how much drug goes into the body fluid.</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
          <units>liters per hour (L/hr)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6" spread="67"/>
                    <measurement group_id="O2" value="92.3" spread="596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PKs) of TT223, 3-Week Time Point - Apparent Volume of Distribution During the Terminal Phase After Extra-Vascular Administration (Vz/F), Apparent Volume of Distribution at Steady-State After Extra-Vascular Administration (Vss/F)</title>
        <description>Apparent volume of distribution during the terminal phase after extra-vascular administration (Vz/F) is the apparent volume that contains drug after absorption is complete and drug is no longer being given. Apparent volume of distribution at steady-state after extra-vascular administration (Vss/F) is the apparent volume that contains drug when drug is being given continuously.</description>
        <time_frame>0 (pre-dose), 0.33, 0.5, 1, 2, 3, 4, 6 hours</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 2 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 3 mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PKs) of TT223, 3-Week Time Point - Apparent Volume of Distribution During the Terminal Phase After Extra-Vascular Administration (Vz/F), Apparent Volume of Distribution at Steady-State After Extra-Vascular Administration (Vss/F)</title>
          <description>Apparent volume of distribution during the terminal phase after extra-vascular administration (Vz/F) is the apparent volume that contains drug after absorption is complete and drug is no longer being given. Apparent volume of distribution at steady-state after extra-vascular administration (Vss/F) is the apparent volume that contains drug when drug is being given continuously.</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
          <units>liters (L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vz/F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124" spread="129"/>
                    <measurement group_id="O2" value="137" spread="645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vss/F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163" spread="97"/>
                    <measurement group_id="O2" value="202" spread="519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PKs) of LY2428757, 3-Week Time Point - Maximum Observed Drug Concentration (Cmax)</title>
        <description>Maximum observed drug concentration (Cmax) is the maximum observed concentration of drug. LY2428757 concentrations were collected at only a single timepoint; therefore, pharmacokinetic (PK) parameters could not be modeled from the data. Analysis was not done due to insufficient time points being collected.</description>
        <time_frame>0 (pre-dose)</time_frame>
        <population>Analyses were not conducted due to insufficient time points being collected; zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PKs) of LY2428757, 3-Week Time Point - Maximum Observed Drug Concentration (Cmax)</title>
          <description>Maximum observed drug concentration (Cmax) is the maximum observed concentration of drug. LY2428757 concentrations were collected at only a single timepoint; therefore, pharmacokinetic (PK) parameters could not be modeled from the data. Analysis was not done due to insufficient time points being collected.</description>
          <population>Analyses were not conducted due to insufficient time points being collected; zero participants were analyzed.</population>
          <units>nanograms per milliliter (ng/ml)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale (VAS) for Nausea</title>
        <description>The Visual Analog Scale (VAS) is a continuous measure for degree of nausea and/or gastrointestinal discomfort. Each of these scales is 100 millimeters (mm) in length with 0 meaning no nausea at all and 100 meaning extreme nausea. Participants record self-assessment of how much nausea they have had, from 0 to 100, during the time interval indicated.</description>
        <time_frame>4 weeks, 6 months</time_frame>
        <population>Each visit includes participants who received at least 1 dose of TT223 or its placebo who had both a baseline value and a value at that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale (VAS) for Nausea</title>
          <description>The Visual Analog Scale (VAS) is a continuous measure for degree of nausea and/or gastrointestinal discomfort. Each of these scales is 100 millimeters (mm) in length with 0 meaning no nausea at all and 100 meaning extreme nausea. Participants record self-assessment of how much nausea they have had, from 0 to 100, during the time interval indicated.</description>
          <population>Each visit includes participants who received at least 1 dose of TT223 or its placebo who had both a baseline value and a value at that visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=38, 37, 38, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="19.21"/>
                    <measurement group_id="O2" value="5.7" spread="11.27"/>
                    <measurement group_id="O3" value="8.4" spread="17.12"/>
                    <measurement group_id="O4" value="4.7" spread="11.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks (n=33, 27, 34, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" spread="20.49"/>
                    <measurement group_id="O2" value="27.6" spread="26.67"/>
                    <measurement group_id="O3" value="11.9" spread="19.66"/>
                    <measurement group_id="O4" value="9.1" spread="11.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=27, 24, 30, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="11.31"/>
                    <measurement group_id="O2" value="3.4" spread="4.86"/>
                    <measurement group_id="O3" value="7.3" spread="18.38"/>
                    <measurement group_id="O4" value="8.1" spread="12.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Waist Circumference at 6-Month Endpoint</title>
        <description>Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
        <time_frame>Baseline (Week -1), 6 months</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Waist Circumference at 6-Month Endpoint</title>
          <description>Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
          <units>centimeters (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" spread="5.276"/>
                    <measurement group_id="O2" value="-0.60" spread="2.433"/>
                    <measurement group_id="O3" value="-0.16" spread="2.599"/>
                    <measurement group_id="O4" value="-0.33" spread="3.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>7-point Profile, Self-Monitored Blood Glucose (SMBG) Values</title>
        <description>The 7-point average is the average of the mean value of all time points for the visit. Time points included pre-morning meal, 2 hours after morning meal, pre-midday meal, 2 hours after midday meal, pre-evening meal, 2 hours after evening meal, and bedtime.</description>
        <time_frame>Baseline (Week -1), 4 weeks, 6 months</time_frame>
        <population>Each visit includes participants who received at least 1 dose of TT223 or its placebo who had both a baseline value and a value at that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>7-point Profile, Self-Monitored Blood Glucose (SMBG) Values</title>
          <description>The 7-point average is the average of the mean value of all time points for the visit. Time points included pre-morning meal, 2 hours after morning meal, pre-midday meal, 2 hours after midday meal, pre-evening meal, 2 hours after evening meal, and bedtime.</description>
          <population>Each visit includes participants who received at least 1 dose of TT223 or its placebo who had both a baseline value and a value at that visit.</population>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks (n=31, 22, 30, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.75" spread="29.973"/>
                    <measurement group_id="O2" value="147.10" spread="24.514"/>
                    <measurement group_id="O3" value="142.38" spread="32.199"/>
                    <measurement group_id="O4" value="169.23" spread="55.866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=24, 19, 23, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.18" spread="46.455"/>
                    <measurement group_id="O2" value="177.50" spread="49.379"/>
                    <measurement group_id="O3" value="176.33" spread="38.900"/>
                    <measurement group_id="O4" value="172.05" spread="28.688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 7-Point Profile, Self-Monitored Blood Glucose (SMBG) at 4-Week and 6-Month Endpoints</title>
        <description>7-point average=average of mean value of all time points for visit (premorning meal, 2-hours postmorning meal, premidday meal, 2-hours postmidday meal, preevening meal, 2-hours postevening meal, bedtime). Values represent mean of values collected same time on 3 separate days within week prior to visit. Values from repeated measures included fixed categorical effects: treatment, baseline therapy strata, visit, treatment-by-visit, continuous fixed covariate baseline &lt;7-point average glucose value or time point presented. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
        <time_frame>Baseline (Week -1), 4 weeks, 6 months</time_frame>
        <population>Intent-to-treat (ITT): All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value for the variable being analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 7-Point Profile, Self-Monitored Blood Glucose (SMBG) at 4-Week and 6-Month Endpoints</title>
          <description>7-point average=average of mean value of all time points for visit (premorning meal, 2-hours postmorning meal, premidday meal, 2-hours postmidday meal, preevening meal, 2-hours postevening meal, bedtime). Values represent mean of values collected same time on 3 separate days within week prior to visit. Values from repeated measures included fixed categorical effects: treatment, baseline therapy strata, visit, treatment-by-visit, continuous fixed covariate baseline &lt;7-point average glucose value or time point presented. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
          <population>Intent-to-treat (ITT): All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value for the variable being analyzed.</population>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Average 4 weeks (n=31,22,30,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.28" spread="5.082"/>
                    <measurement group_id="O2" value="-45.03" spread="6.192"/>
                    <measurement group_id="O3" value="-41.18" spread="5.215"/>
                    <measurement group_id="O4" value="-18.95" spread="7.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-morning meal fasting 4 weeks (n=31,22,30,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.30" spread="5.335"/>
                    <measurement group_id="O2" value="-42.95" spread="6.526"/>
                    <measurement group_id="O3" value="-32.41" spread="5.466"/>
                    <measurement group_id="O4" value="-5.89" spread="7.529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours after morning meal 4 weeks (n=30,21,29,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.41" spread="6.094"/>
                    <measurement group_id="O2" value="-63.72" spread="7.409"/>
                    <measurement group_id="O3" value="-51.70" spread="6.158"/>
                    <measurement group_id="O4" value="-23.80" spread="8.313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-midday meal 4 weeks (n=30,22,29,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.76" spread="5.950"/>
                    <measurement group_id="O2" value="-30.83" spread="7.088"/>
                    <measurement group_id="O3" value="-32.86" spread="6.048"/>
                    <measurement group_id="O4" value="-14.96" spread="8.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours after midday meal 4 weeks (n=30,22,29,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.64" spread="6.719"/>
                    <measurement group_id="O2" value="-38.90" spread="8.037"/>
                    <measurement group_id="O3" value="-39.30" spread="6.907"/>
                    <measurement group_id="O4" value="-22.19" spread="9.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-evening meal 4 weeks (n=30,22,29,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.67" spread="5.565"/>
                    <measurement group_id="O2" value="-28.36" spread="6.663"/>
                    <measurement group_id="O3" value="-30.87" spread="5.760"/>
                    <measurement group_id="O4" value="-16.85" spread="7.721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours after evening meal 4 weeks (n=30,22,29,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.72" spread="6.728"/>
                    <measurement group_id="O2" value="-53.39" spread="8.125"/>
                    <measurement group_id="O3" value="-51.07" spread="6.927"/>
                    <measurement group_id="O4" value="-29.01" spread="9.574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bedtime 4 weeks (n=28,21,28,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.44" spread="7.112"/>
                    <measurement group_id="O2" value="-44.50" spread="8.378"/>
                    <measurement group_id="O3" value="-41.22" spread="7.108"/>
                    <measurement group_id="O4" value="-14.66" spread="9.492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average 6 months (n=24,19,23,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.66" spread="7.693"/>
                    <measurement group_id="O2" value="-11.70" spread="8.759"/>
                    <measurement group_id="O3" value="-5.76" spread="7.970"/>
                    <measurement group_id="O4" value="-13.07" spread="10.751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-morning meal fasting 6 months (n=24,19,23,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.00" spread="5.981"/>
                    <measurement group_id="O2" value="-4.89" spread="6.869"/>
                    <measurement group_id="O3" value="-10.48" spread="6.236"/>
                    <measurement group_id="O4" value="-6.45" spread="8.314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2hours after morning meal 6 months (n=23,19,23,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.25" spread="8.654"/>
                    <measurement group_id="O2" value="-18.40" spread="9.631"/>
                    <measurement group_id="O3" value="-14.84" spread="8.739"/>
                    <measurement group_id="O4" value="-27.48" spread="11.755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-midday meal 6 months (n=24,19,23,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.76" spread="8.345"/>
                    <measurement group_id="O2" value="3.95" spread="9.452"/>
                    <measurement group_id="O3" value="-0.96" spread="8.558"/>
                    <measurement group_id="O4" value="-9.54" spread="11.554"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2hours after midday meal 6 months (n=24,19,23,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.51" spread="9.418"/>
                    <measurement group_id="O2" value="-4.15" spread="10.722"/>
                    <measurement group_id="O3" value="4.67" spread="9.788"/>
                    <measurement group_id="O4" value="-12.71" spread="13.152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-evening meal 6 months (n=24,19,23,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.61" spread="8.562"/>
                    <measurement group_id="O2" value="-7.53" spread="9.727"/>
                    <measurement group_id="O3" value="1.53" spread="8.881"/>
                    <measurement group_id="O4" value="-15.57" spread="11.958"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2hours after evening meal 6 months (n=24,19,23,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.20" spread="10.373"/>
                    <measurement group_id="O2" value="-20.89" spread="11.815"/>
                    <measurement group_id="O3" value="-9.98" spread="10.726"/>
                    <measurement group_id="O4" value="-7.62" spread="14.491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bedtime 6 months (n=21,18,22,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.27" spread="9.684"/>
                    <measurement group_id="O2" value="-21.61" spread="10.612"/>
                    <measurement group_id="O3" value="-6.40" spread="9.599"/>
                    <measurement group_id="O4" value="-3.79" spread="13.150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lipase at Week 0, Week 4, and 6-Month Endpoints</title>
        <description>Values obtained from repeated measures analysis, which included the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline serum lipase. Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
        <time_frame>Baseline (Week -1), Week 0, 4 weeks, 6 months</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lipase at Week 0, Week 4, and 6-Month Endpoints</title>
          <description>Values obtained from repeated measures analysis, which included the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline serum lipase. Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
          <units>units per liter (U/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (n=38, 36, 38, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="7.89"/>
                    <measurement group_id="O2" value="8.1" spread="8.11"/>
                    <measurement group_id="O3" value="15.8" spread="7.89"/>
                    <measurement group_id="O4" value="2.3" spread="11.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks (n=32, 27, 34, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="9.92"/>
                    <measurement group_id="O2" value="10.1" spread="10.53"/>
                    <measurement group_id="O3" value="40.5" spread="9.79"/>
                    <measurement group_id="O4" value="0.4" spread="14.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=28, 23, 30, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="4.52"/>
                    <measurement group_id="O2" value="-5.0" spread="4.95"/>
                    <measurement group_id="O3" value="7.0" spread="4.42"/>
                    <measurement group_id="O4" value="-3.1" spread="6.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Amylase at 6-Month Endpoint</title>
        <description>Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
        <time_frame>Baseline (Week -1), 6 months</time_frame>
        <population>Intent-to-treat (ITT): All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline amylase value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Amylase at 6-Month Endpoint</title>
          <description>Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
          <population>Intent-to-treat (ITT): All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline amylase value.</population>
          <units>units/liter (U/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="3.15"/>
                    <measurement group_id="O2" value="-4.5" spread="3.45"/>
                    <measurement group_id="O3" value="1.5" spread="3.01"/>
                    <measurement group_id="O4" value="-10.3" spread="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With 2-Fold Elevation of Lipase and/or Amylase at Any Timepoint</title>
        <description>Values obtained from repeated measures analysis, which included the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline amylase.</description>
        <time_frame>Baseline (Week -1) through 6 months</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With 2-Fold Elevation of Lipase and/or Amylase at Any Timepoint</title>
          <description>Values obtained from repeated measures analysis, which included the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline amylase.</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lipase &gt;= 2 times the upper limit of normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase &gt;=2 times the upper limit of normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Hypoglycemia</title>
        <description>Calculation of frequency of low glucose for time period. Hypoglycemia≥1 events: severe&lt;50mg/dL, unable to treat self/recover after treatment; documented symptomatic≤70mg/dL, adrenergic/neuroglycopenic symptoms; asymptomatic≤70mg/dL no symptoms; probable symptomatic glucose missing, adrenergic/neuroglycopenic symptoms; relative&gt;70mg/dL, adrenergic/neuroglycopenic symptoms, nocturnal≤70mg/dL, adrenergic/neuroglycopenic symptoms between bedtime/waking. Because number participants who experienced hypoglycemia was low for every arm (1-3/arm) did not model percentage participants with hypoglycemia.</description>
        <time_frame>Baseline (Week -1) through 6 months</time_frame>
        <population>Because the number of hypoglycemia events were too low to model the percentage of hypoglycemia, zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hypoglycemia</title>
          <description>Calculation of frequency of low glucose for time period. Hypoglycemia≥1 events: severe&lt;50mg/dL, unable to treat self/recover after treatment; documented symptomatic≤70mg/dL, adrenergic/neuroglycopenic symptoms; asymptomatic≤70mg/dL no symptoms; probable symptomatic glucose missing, adrenergic/neuroglycopenic symptoms; relative&gt;70mg/dL, adrenergic/neuroglycopenic symptoms, nocturnal≤70mg/dL, adrenergic/neuroglycopenic symptoms between bedtime/waking. Because number participants who experienced hypoglycemia was low for every arm (1-3/arm) did not model percentage participants with hypoglycemia.</description>
          <population>Because the number of hypoglycemia events were too low to model the percentage of hypoglycemia, zero participants were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hypoglycemia</title>
        <description>The number of participants for whom low blood glucose was reported. Hypoglycemia ≥1 events including: severe hypoglycemia(glucose &lt;50mg/dL, unable to treat self or recover after treatment); documented symptomatic (glucose ≤70mg/dL, adrenergic or neuroglycopenic symptoms); asymptomatic (glucose ≤70mg/dL no symptoms); probable symptomatic (glucose missing, adrenergic or neuroglycopenic symptoms); relative (glucose &gt;70mg/dL, adrenergic or neuroglycopenic symptoms), nocturnal (glucose ≤70mg/dL, adrenergic or neuroglycopenic symptoms between bedtime/waking).</description>
        <time_frame>Baseline (Week -1) through 6 months</time_frame>
        <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hypoglycemia</title>
          <description>The number of participants for whom low blood glucose was reported. Hypoglycemia ≥1 events including: severe hypoglycemia(glucose &lt;50mg/dL, unable to treat self or recover after treatment); documented symptomatic (glucose ≤70mg/dL, adrenergic or neuroglycopenic symptoms); asymptomatic (glucose ≤70mg/dL no symptoms); probable symptomatic (glucose missing, adrenergic or neuroglycopenic symptoms); relative (glucose &gt;70mg/dL, adrenergic or neuroglycopenic symptoms), nocturnal (glucose ≤70mg/dL, adrenergic or neuroglycopenic symptoms between bedtime/waking).</description>
          <population>Intent-to-treat (ITT) population: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline value.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adjudicated and Confirmed Deaths and Non-Fatal Cardiovascular (CV) Events at Any Timepoint</title>
        <description>The protocol specified that deaths and nonfatal cardiovascular (CV) adverse events (AEs) be adjudicated by independent physician(s) with cardiology or neurology experience. The CV AEs to be adjudicated were protocol-defined as myocardial infarction (MI), hospitalization for unstable angina or for heart failure, coronary interventions (coronary artery bypass graft or percutaneous coronary intervention [PCI]) and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack (TIA). 3 CV events were adjudicated by an external independent adjudication committee.</description>
        <time_frame>Baseline (Week -1) through 6 months</time_frame>
        <population>All participants who received at least 1 dose of TT223 or its placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adjudicated and Confirmed Deaths and Non-Fatal Cardiovascular (CV) Events at Any Timepoint</title>
          <description>The protocol specified that deaths and nonfatal cardiovascular (CV) adverse events (AEs) be adjudicated by independent physician(s) with cardiology or neurology experience. The CV AEs to be adjudicated were protocol-defined as myocardial infarction (MI), hospitalization for unstable angina or for heart failure, coronary interventions (coronary artery bypass graft or percutaneous coronary intervention [PCI]) and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack (TIA). 3 CV events were adjudicated by an external independent adjudication committee.</description>
          <population>All participants who received at least 1 dose of TT223 or its placebo.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Insulin at 4-Week and 6-Month Endpoints</title>
        <description>Values obtained from repeated measures analysis, which included the fixed categorical effects of treatment, baseline therapy strata (metformin versus diet and exercise [D&amp;E]), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline Fasting Insulin. Fasting insulin is the Mixed-Meal Tolerance Test (MMTT) insulin assessment at timepoint 0, where available, otherwise it is the assessment taken from the fasting laboratory measurements obtained during the clinic visit. Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
        <time_frame>Baseline (Week -1), 4 weeks, 6 months</time_frame>
        <population>Intent-to-treat: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline fasting insulin value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Insulin at 4-Week and 6-Month Endpoints</title>
          <description>Values obtained from repeated measures analysis, which included the fixed categorical effects of treatment, baseline therapy strata (metformin versus diet and exercise [D&amp;E]), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline Fasting Insulin. Fasting insulin is the Mixed-Meal Tolerance Test (MMTT) insulin assessment at timepoint 0, where available, otherwise it is the assessment taken from the fasting laboratory measurements obtained during the clinic visit. Change from baseline means the absolute change from baseline (endpoint-baseline).</description>
          <population>Intent-to-treat: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline fasting insulin value.</population>
          <units>microinternational units/milliliter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks (n=31, 25, 32, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="4.57"/>
                    <measurement group_id="O2" value="-4.2" spread="4.89"/>
                    <measurement group_id="O3" value="4.7" spread="4.49"/>
                    <measurement group_id="O4" value="0.7" spread="6.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=23, 20, 22, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="4.03"/>
                    <measurement group_id="O2" value="-4.2" spread="4.41"/>
                    <measurement group_id="O3" value="2.8" spread="3.95"/>
                    <measurement group_id="O4" value="-7.2" spread="5.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Homeostatic Model Assessment (HOMA) at 3-Week and 6-Month Endpoints</title>
        <description>Values from repeated measures include fixed categorical effects of treatment, baseline therapy strata, visit, treatment-by-visit, continuous fixed covariate of baseline HOMA derived beta-cell function (HOMA-B). HOMA=index of function of cells that make insulin. Indices derived from fasting glucose and insulin concentrations. HOMA is measurement reflecting fasting plasma glucose and insulin. Has no defined minimum/maximum value. HOMA-B values generated from table reflecting values derived from Oxford HOMA2 model calculator. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
        <time_frame>Baseline (Week -1), 3 weeks, 6 months</time_frame>
        <population>Intent-to-treat: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline HOMA value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2428757 Plus TT223 3mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>LY2428757 Plus TT223 2mg</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY2428757 Plus TT223 Placebo</title>
            <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY Placebo Plus TT223 Placebo</title>
            <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Homeostatic Model Assessment (HOMA) at 3-Week and 6-Month Endpoints</title>
          <description>Values from repeated measures include fixed categorical effects of treatment, baseline therapy strata, visit, treatment-by-visit, continuous fixed covariate of baseline HOMA derived beta-cell function (HOMA-B). HOMA=index of function of cells that make insulin. Indices derived from fasting glucose and insulin concentrations. HOMA is measurement reflecting fasting plasma glucose and insulin. Has no defined minimum/maximum value. HOMA-B values generated from table reflecting values derived from Oxford HOMA2 model calculator. Change from baseline=absolute change from baseline (endpoint-baseline).</description>
          <population>Intent-to-treat: All participants who received at least 1 dose of TT223 or its placebo with both a baseline and at least 1 post-baseline HOMA value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 weeks (n=26, 23, 26, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.12" spread="7.605"/>
                    <measurement group_id="O2" value="34.73" spread="8.093"/>
                    <measurement group_id="O3" value="37.76" spread="7.597"/>
                    <measurement group_id="O4" value="-14.99" spread="10.193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=19, 18, 19, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.05" spread="9.128"/>
                    <measurement group_id="O2" value="4.41" spread="9.415"/>
                    <measurement group_id="O3" value="19.17" spread="9.111"/>
                    <measurement group_id="O4" value="-9.01" spread="11.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LY2428757 Plus TT223 3mg</title>
          <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 3 mg subcutaneous injection daily for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>LY2428757 Plus TT223 2mg</title>
          <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 2 mg subcutaneous injection daily for 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>LY2428757 Plus TT223 Placebo</title>
          <description>Weekly LY2428757 14 mg subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
        </group>
        <group group_id="E4">
          <title>LY Placebo Plus TT223 Placebo</title>
          <description>Weekly LY2428757 placebo subcutaneous injection for 5 weeks plus TT223 placebo subcutaneous injection daily for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="38"/>
                <counts group_id="E2" events="22" subjects_affected="15" subjects_at_risk="37"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E2" events="11" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

